Skip to main content

Table 3 Clinical efficiency of epigenetic drugs agents in PTCL

From: Epigenetic alterations and advancement of treatment in peripheral T-cell lymphoma

Drug

Patients distribution

Response

(ORR, DOR, CR)

Phase

Chidamide [54]

N = 79

PTCL-NOS (34%), ALCL (20%),

ENKTL: (20%)

ORR:28%

Median PFS: 2.1 months OS:21.4 months

CR/Cru:14%

Median DOR: 9.9 month

II

Chidamide-Combined Chemotherapy [56]

N = 127

ORR = 51.18%

DCR = 74.02%

Median PFS = 152 day

II

Chidamide [56]

N = 383 PTCL monotherapy (n = 256)

Monotherapy

ORR = 39.06%

DCR = 64.45%,

median (PFS) = 129 days

II

Vorinostat [60] combination with chop

N = 14

Median PFS = 79%

OS = 82%

Median response duration = 29 months

I

Romidepsin [66, 67]

N = 130

ORR = 25%

CR/Cru = 15%

median PFS = 13.4 ~ 29 months. median DOR = 28 months

II

Romidepsin [68]

N = 47 PTCL

ORR = 38%,CR = 18% median DOR = 8.9 months

II

Romidepsin plus chop [70]

N = 37

ORR = 69%

PFS = 41%

OS = 71%,

Ib/II

Pralatrexate + Romidepsin [72]

N = 29

ORR = 71% (10/14)

II

Romidepsin [73]

N = 27

AITL

ORR = 33%

 

Belinostat [74]

N = 24 PTCL

ORR = 25%,

CR = 8%, DOR = 13.6mo

II

Belinostat [75, 76]

N = 129

ORR (CR, PR) = 25.8%

Median DoR = 13.6 months Median PFS = 1.6 months

Median OS = 7.9 months

II

5-Azacytidine [125, 126]

N = 12

ORR = 75%,

median PFS = 15 months median OS = 21 months

Clinic trial

  1. AITL angioimmunoblastic T-cell lymphoma, PTCL peripheral T-cell lymphoma, Median PFS median progression-free survival, OS overall survival, DOR duration of response, Median DOR median duration of response, CR complete response, DCR disease control rate, PTCL-NOS PTCL not otherwise specified, ALCL anaplastic large-cell lymphoma, ENKTL extranodal natural killer (NK)/T-cell lymphoma, nasal type